Getting a drug to market is no easy task. It takes years of hard work and financial investment. But the job doesn’t end with a long-awaited FDA approval. If your drug is a targeted treatment, you have the added task of developing and commercializing a test to identify the right patients for your treatment. This typically requires a partnership with a companion diagnostics (CDx) developer. But the job does not end there. Indeed, just getting a targeted therapy and CDx on the market does not ensure that your targeted treatment will ultimately reach all the patients who could benefit. In reality, more than 150,000 patients are missed each year because of issues related to slow test turnaround times, poor sample management and inconsistent test results.1 For the pharma industry market, this translates into more than $16B in permanently lost revenue, which may be surprising. 1
How could so many patients be missing out on the promising opportunity of receiving targeted treatment? What is driving this monumental loss in revenue? Issues result from common hurdles in CDx development and commercialization that you might not even be aware of. Some of these testing hurdles include:
Indeed, partnering with a CDx developer does not necessarily prepare you for any of these testing hurdles, obstructing the diagnostic development and commercialization landscape and, ultimately, preventing seamless test adoption. You may not realize it, but the typical CDx developer is not in the business of anticipating and circumventing these testing hurdles. Instead, you need the crucial additional help of an industry leader in data analytics and implementation services for diagnostic commercialization. This is where Diaceutics comes in.
Diaceutics works with pharmaceutical companies and its worldwide network of laboratories to help more patients get the right treatment at the right time through better, more efficient diagnostic testing. To do so, Diaceutics prepares and fortifies pharma with the following critical services:
Explore the following case studies demonstrating how Diaceutics has helped multiple pharma clients in their journeys from targeted therapy conception to test adoption and maximal patient reach.
1 FT US Healthcare & Life Sciences Summit, May 2017. “Transforming the pharma business model to prevent lost treatment opportunities and optimize return on investment” Keeling, P.